[Treatment of Graves' ophthalmopathy with oral or intravenous corticosteroids].
D000284:Administration, Oral; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage* / Q000009:adverse effects; D006111:Graves Disease / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007275:Injections, Intravenous; D008297:Male; D015201:Meta-Analysis as Topic; D008775:Methylprednisolone / Q000008:administration & dosage / Q000009:adverse effects; D011239:Prednisolone / Q000008:administration & dosage / Q000009:adverse effects; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects; D016032:Randomized Controlled Trials as Topic; D013997:Time Factors
D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D016756:Immunoglobulins, Intravenous; D011239:Prednisolone; D011241:Prednisone; D008775:Methylprednisolone
Die systemische Glukokortikoidtherapie in der Behandlung der endokrinen Orbitopathie.